



## **OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)**

September 14, 2016

WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 14, 2016-- OvaScience<sup>SM</sup> (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement awards to its newly appointed Chief Financial Officer, Christophe Couturier, and Executive Vice President, Regulatory, Clinical, Medical Affairs and Quality Assurance, Karen Long. The awards were approved by OvaScience's Compensation Committee on September 8, 2016 as an inducement material to each of them entering into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).

The inducement grant to Mr. Couturier consisted of an option to purchase up to 200,000 shares of common stock and the inducement grant to Ms. Long consisted of an option to purchase up to 120,000 shares of common stock. The inducement grants are exercisable at a price of \$7.15 per share, equal to the closing price per share of OvaScience's common stock as reported by NASDAQ on September 8, 2016. The stock options vest over four years, with 25% of the shares vesting on September 6, 2017 for Mr. Couturier and 25% of the shares vesting on August 22, 2017 for Ms. Long, and an additional 6.25% of the shares vesting at the end of each subsequent quarter thereafter, subject to each executive's continued service relationship with OvaScience through the applicable vesting dates.

In addition, OvaScience also announced the grant of inducement awards to purchase an aggregate of 407,500 shares of its common stock to 18 newly hired employees. These grants were also made in accordance with NASDAQ Listing Rule 5635(c)(4). The awards were approved by OvaScience's Compensation Committee on September 8, 2016 as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). These new hire inducement grants are exercisable at a price of \$7.15 per share, equal to the closing price per share of OvaScience's common stock as reported by NASDAQ on September 8, 2016. These stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of each employee's hire date and an additional 6.25% of the shares vesting at the end of each subsequent quarter thereafter, subject to the new employee's continued service relationship with the Company through the applicable vesting dates.

### **About OvaScience**

OvaScience, Inc. (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because it believes women deserve more options. Each OvaScience treatment is based on the Company's proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC<sup>SM</sup>) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT<sup>SM</sup> treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience is developing the OvaPrime<sup>SM</sup> treatment, which could increase a woman's egg reserve, and the OvaTure<sup>SM</sup> treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160914006307/en/>

Source: OvaScience

### **Media and Investor Contact:**

#### **OvaScience**

Jennifer Viera, 617-420-8748

[jviera@ovascience.com](mailto:jviera@ovascience.com)